Efficacy and safety of insulin degludec U100 and insulin glargine U100 in combination with meal-time bolus insulin in hospitalized patients with type 2 diabetes: an open-label, randomized controlled study
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
The short-term efficacy and safety of insulin degludec U100 (IDeg) in patients with type 2 diabetes have not been reported widely. We compared insulin IDeg and insulin glargine U100 (IGla) for glycemic control and glucose variability in hospitalized patients with type 2 diabetes. In an open-label, multicenter, randomized controlled trial, 74 patients were randomly assigned to either the IDeg (36 patients) or IGla (38 patients) group and were administered with basal-bolus therapy during hospitalization. Following the start of the treatment, on day 11, glucose variability was assessed by continuous glucose monitoring. A fasting blood glucose level of 110 mg/dL and 2-hour postprandial blood glucose level of 180 mg/dL throughout at least one day during the observation period were achieved in 31.3% (10/32) and 30.6% (11/36) of the patients in the IDeg and IGla groups, respectively. The 6-point self-monitoring of blood glucose profiles showed a significant difference between the two groups. On day 7, the intra-day variation was larger in the IDeg group than in the IGla group. The incidence of hypoglycemia or glucose variability was comparable in the two groups. This study suggests that short-term efficacy and safety of IDeg and IGla in patients with type 2 diabetes during the initial phase of basal-bolus therapy were comparable, and these results can help in deciding which treatment to opt for.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Basal insulin and cardiovascular and other outcomes in dysglycemia
The ORIGIN Trial Investigators (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203858 · Cited by 1,636
Pancreatic β Cell Dedifferentiation as a Mechanism of Diabetic β Cell Failure
Talchai, C., Xuan, S., Lin, H. V., Sussel, L., & Accili, D. (2012) · Cell · doi:10.1016/j.cell.2012.07.029 · Cited by 1,415
Umpierre, D. (2011) · JAMA · doi:10.1001/jama.2011.576 · Cited by 1,358
Efficacy and safety of degludec versus glargine in type 2 diabetes.
Marso, S. P., McGuire, D. K., Zinman, B., Poulter, N. R., Emerson, S. S., Pieber, T. R., Pratley, R. E., Haahr, P.-M., Lange, M., Brown-Frandsen, K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615692 · Cited by 574 · cited 1×
“Moreover, IDeg is safer than IGla with respect to fre‐ quency of severe hypoglycemia in a long-term study in patients with type 2 diabetes [30].”
Background(DPS), F. T. F. D. P. S., Lindström, J., Peltonen, M., Eriksson, J. G., Ilanne-Parikka, P., Aunola, S., Keinänen-Kiukaanniemi, S., Uusitupa, M., & Tuomilehto, J. (2013) · Diabetologia · doi:10.1007/s00125-012-2752-5 · Cited by 551
Design of the Novel Protraction Mechanism of Insulin Degludec, an Ultra-long-Acting Basal Insulin
Jonassen, I., Havelund, S., Hoeg-Jensen, T., Steensgaard, D. B., Wahlund, P.-O., & Ribel, U. (2012) · Pharmaceutical Research · doi:10.1007/s11095-012-0739-z · Cited by 448
The evidence for the effectiveness of medical nutrition therapy in diabetes management
Pastors, J. G., Warshaw, H., Daly, A., Franz, M., & Kulkarni, K. (2002) · Diabetes Care · doi:10.2337/diacare.25.3.608 · Cited by 434
Correlates of Insulin Injection Omission
Peyrot, M., Rubin, R. R., Kruger, D. F., & Travis, L. B. (2010) · Diabetes Care · doi:10.2337/dc09-1348 · Cited by 407
Heller, S., Buse, J., Fisher, M., Garg, S., Marre, M., Merker, L., Renard, E., Russell-Jones, D., Philotheou, A., Francisco, A. M. O., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60204-9 · Cited by 402
Heise, T., Hermanski, L., Nosek, L., Feldman, A., Rasmussen, S., & Haahr, H. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01627.x · Cited by 397
Ratner, R. E., Gough, S. C. L., Mathieu, C., Del Prato, S., Bode, B., Mersebach, H., Endahl, L., & Zinman, B. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12032 · Cited by 346
Insulin Degludec Versus Insulin Glargine in Insulin-Naive Patients With Type 2 Diabetes
Zinman, B., Philis-Tsimikas, A., Cariou, B., Handelsman, Y., Rodbard, H. W., Johansen, T., Endahl, L., Mathieu, C., & on behalf of the NN1250-3579 (BEGIN Once Long) Trial Investigators (2012) · Diabetes Care · doi:10.2337/dc12-1205 · Cited by 336
Ultra‐long‐acting insulin degludec has a flat and stable glucose‐lowering effect in type 2 diabetes
Heise, T., Nosek, L., Bøttcher, S. G., Hastrup, H., & Haahr, H. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01638.x · Cited by 331 · cited 2×
“In recent years, how‐ ever, IDeg has appeared on the market as the new, longacting, soluble insulin, with a better stable concentration in the blood compared to IGla [14-17].”
BackgroundMeneghini, L., Atkin, S. L., Gough, S. C. L., Raz, I., Blonde, L., Shestakova, M., Bain, S., Johansen, T., Begtrup, K., Birkeland, K. I., et al. (2013) · Diabetes Care · doi:10.2337/dc12-1668 · Cited by 226
Mathieu, C., Hollander, P., Miranda-Palma, B., Cooper, J., Franek, E., Russell-Jones, D., Larsen, J., Tamer, S. C., Bain, S. C., & on behalf of the NN1250-3770 (BEGIN: Flex T1) Trial Investigators (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-3249 · Cited by 219
Lane, W., Bailey, T. S., Gerety, G., Gumprecht, J., Philis-Tsimikas, A., Hansen, C. T., Nielsen, T. S. S., Warren, M., Group Information, & 1, T. S. (2017) · JAMA · doi:10.1001/jama.2017.7115 · Cited by 206 · cited 2×
“Regarding safety, previous studies have shown that the risk of hypoglycemia particularly nocturnal, is lower with IDeg than with IGla [18-20].”
BackgroundMavros, Y., Kay, S., Anderberg, K. A., Baker, M. K., Wang, Y., Zhao, R., Meiklejohn, J., Climstein, M., O’Sullivan, A., de Vos, N., et al. (2013) · Diabetes Care · doi:10.2337/dc12-2196 · Cited by 118
Onishi, Y., Iwamoto, Y., Yoo, S. J., Clauson, P., Tamer, S. C., & Park, S. (2013) · Journal of Diabetes Investigation · doi:10.1111/jdi.12102 · Cited by 102 · cited 1×
“The sample size was calculated based on the assump‐ tion that the true probability of achieving the target glycemic control was 40% in each group [22-24].”
Method
Cited by
Pasquel, F. J., Lansang, M. C., Khowaja, A., Urrutia, M. A., Cardona, S., Albury, B., Galindo, R. J., Fayfman, M., Davis, G., Migdal, A., et al. (2020) · Diabetes Care · doi:10.2337/dc19-1940 · Cited by 45
“Of interest, a recent smaller RCT (n 5 74) examined the efficacy of the other available longacting insulin degludec compared with glargine U100 in patients with T2D admitted for glycemic control optimization (27).”
BackgroundGalindo, R. J., Pasquel, F. J., Vellanki, P., Alicic, R., Lam, D. W., Fayfman, M., Migdal, A. L., Davis, G. M., Cardona, S., Urrutia, M. A., et al. (2022) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14544 · Cited by 26
Cheng, A. Y. Y., Wong, J., Freemantle, N., Acharya, S. H., & Ekinci, E. (2020) · Diabetes Therapy · doi:10.1007/s13300-020-00925-8 · Cited by 20
Perez, A., Carrasco-Sánchez, F. J., González, C., Seguí-Ripoll, J. M., Trescolí, C., Ena, J., Borrell, M., & Gomez Huelgas, R. (2020) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2020-001518 · Cited by 16
Metadata
- Authors
- Suzuki, J., Yamakawa, T., Oba, M., Nagakura, J., Shigematsu, E., Tamura, H., Takahashi, K., Okamoto, Y., Sakamoto, R., Shinoda, M., Takano, T., Kadonosono, K., & Terauchi, Y.
- Venue
- Endocrine Journal
- Publisher
- Japan Endocrine Society
- Published
- 2019
- Volume
- 66
- Issue
- 11
- Pages
- 971-982
- ISSN
- 0918-8959 (ISSN-L)
- 1348-4540
- OpenAlex
- W2955471725
- Cited by
- 13
- References
- 18
- FWCI
- 1.72
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.